title: Effects of antihypertensive drugs on cholesterol metabolism of human mononuclear leukocytes and hepatoma cells.
abstract: OBJECTIVE
  Primary prevention trials of antihypertensive therapy have shown conflicting results on coronary events. Potential interference of antihypertensive agents with cellular lipid metabolism may alter the atherosclerotic risk of individuals.
  
  
  METHODS
  The effects of the calcium antagonist's verapamil, diltiazem, and nifedipine and of the beta-blockers propranolol and metoprolol on low density lipoprotein (LDL) receptor activity, cholesterol esterification rate, oleate incorporation in triglycerides and sterol synthesis were studied in freshly isolated human leukocytes and HEP G2 cells.
  
  
  RESULTS
  Up to a concentration of 3-10 mumol/L, verapamil, propranolol, and metoprolol led to an increased cellular content of 125I-LDL by an inhibition of degradation. In mononuclear cells verapamil stimulated accumulation and degradation. No effect on binding was observed. Diltiazem was only stimulatory on 125I-LDL processing in leukocytes. Beta blockers and verapamil significantly reduced the LDL mediated 14C-oleate incorporation in cholesterol esters. In the presence of 25-hydroxycholesterol the esterification was not diminished, which suggests that cholesterolacyltransferase (ACAT) was not affected per se. Whereas all the agents induced the synthesis of lanosterol, metoprolol inhibited cholesterol synthesis. None of the agents had a significant influence on 14C-oleate incorporation in triglycerides, suggesting a specific influence on cholesterol metabolism.
  
  
  CONCLUSIONS
  Antihypertensive drugs affect the cholesterol metabolism on a cellular level. Mechanisms are an interference with degradation of LDL and consequent alterations of cholesterol esterification. Using leukocytes as peripheral cells and HEP G2 as a model of human liver, these results may have importance when antihypertensive long-term therapy is conducted for primary or secondary prevention of atherosclerotic complications.
authors.affiliation: Abt. für Herzchirurgie, Universitäts-Krankenhaus Eppendorf, Hamburg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Naegele
authors.forename: B
authors.initials: B
authors.lastname: Behnke
authors.forename: A
authors.initials: A
authors.lastname: Gebhardt
authors.forename: M
authors.initials: M
authors.lastname: Strohbeck
mesh_terms: D000959:Antihypertensive Agents / Q000494:pharmacology*; D006528:Carcinoma, Hepatocellular / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism*; D004110:Diltiazem / Q000494:pharmacology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000187:drug effects* / Q000378:metabolism*; D008113:Liver Neoplasms / Q000378:metabolism*; D008790:Metoprolol / Q000494:pharmacology; D009543:Nifedipine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014700:Verapamil / Q000494:pharmacology
chemical_list: D000959:Antihypertensive Agents; D002784:Cholesterol; D011433:Propranolol; D014700:Verapamil; D004110:Diltiazem; D008790:Metoprolol; D009543:Nifedipine